Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last 148.00 GBp
Change Today +5.00 / 3.50%
Volume 316.6K
PRTC On Other Exchanges
Symbol
Exchange
London
OTC US
As of 8:23 AM 08/5/15 All times are local (Market data is delayed by at least 15 minutes).

puretech health plc (PRTC) Snapshot

Open
148.00 GBp
Previous Close
143.00 GBp
Day High
150.00 GBp
Day Low
148.00 GBp
52 Week High
06/22/15 - 184.00 GBp
52 Week Low
08/4/15 - 143.00 GBp
Market Cap
351.3M
Average Volume 10 Days
233.3K
EPS TTM
--
Shares Outstanding
237.4M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for PURETECH HEALTH PLC (PRTC)

Related News

No related news articles were found.

puretech health plc (PRTC) Related Businessweek News

No Related Businessweek News Found

puretech health plc (PRTC) Details

PureTech Health plc, a science-driven healthcare company, focuses on developing technologies that seek to address significant healthcare markets. The company, through its subsidiaries and operating companies, engages in developing microbiome immune system drug-discovery platform and drug candidates for the treatment of immune-mediated diseases; and products that seek to induce weight loss and potentially enhance glycaemic control through an orally administered capsule. It is also developing technology and products for the screening, diagnosis, and treatment of neurological disorders, such as ADHD, autism, and depression through computer software; noninvasive neurostimulation treatment for psychiatric disorders, including depression and bipolar disorder; and combination therapy for the treatment of schizophrenia. In addition, the company is developing drug delivery platform for the oral administration of proteins, peptides, and other difficult-to-deliver payloads, including magnetic nanoparticles; and products to generate new human hair follicles and hair. Further, it is developing a platform and products that takes in physiological data from sensors and correlates that data with musical data components; voice-based tools for the passive assessment and tracking of patient health; commensal organism-based products for the improvement of human health; and technology platform to identify experts in healthcare and other research-based disciplines, as well as identifying healthcare expert networks and reviewing their conversations and content on social media. PureTech Health plc was incorporated in 2015 and is based in Boston, Massachusetts.

43 Employees
Last Reported Date: 06/19/15
Founded in 2015

puretech health plc (PRTC) Top Compensated Officers

Chief Executive Officer, Founder and Executiv...
Total Annual Compensation: $614.9K
Executive Vice President, Legal, Finance and ...
Total Annual Compensation: $410.4K
Compensation as of Fiscal Year 2014.

puretech health plc (PRTC) Key Developments

PureTech Names Marko Ahtisaari as CEO

PureTech announced that it has named a former Nokia executive as its first CEO. Marko Ahtisaari, who served as head of design for the Nokia a few years back, was named to head the startup less than a year after it was launched. Ahtisaari, 45, left his position at Nokia in 2013 after four years, a job he came into after Nokia bought the company he previously co-founded and led, a social networking service called Dopplr. Now, he is a Director's Fellow at the MIT Media Lab.

PureTech Health Announces Executive Changes

PureTech announced that Dame Marjorie Scardino, Chairman of the MacArthur Foundation and former CEO of Pearson, has been appointed to PureTech's Board of Directors in the role of Senior Independent Director and that current Board member Joi Ito, MIT Media Lab's Director, has been appointed Board Chairman. Dr. Ben Shapiro, PureTech's outgoing Chairman and co-founder, former Executive Vice President of Basic & External Research at Merck, will remain an active member of the Board. PureTech is also expanding its core team with the addition of Julie DiCarlo, former Head of Global Communications at Cubist Pharmaceuticals, as SVP of Communications and Investor Relations; and Spencer Ball, former Director of Executive Search/Talent Acquisition at PAREXEL, as Vice President of Talent Acquisition. Dame Marjorie Scardino served as Chief Executive of The Economist for 12 years and then from 1997 through 2012 was the Chief Executive of Pearson plc. She is currently the Chairman of The MacArthur Foundation and is also a member of the non-profit boards of Oxfam, The Royal College of Art, and The Carter Center, as well as the for-profit boards of Twitter, where she sits on the audit committee, and IAG (the holding company of British Airways, Iberia and other airlines). Dame Marjorie has received a number of honorary degrees, and in 2003 was dubbed a Dame of the British Empire. She is also a member of the Royal Society of the Arts in the UK and the American Association of Arts and Sciences. Dame Marjorie will be joining PureTech's existing Senior Partners and Board Members, Dr. Robert Langer, PureTech Co-founder and David H. Koch Institute Professor at MIT; Mr. Joi Ito, PureTech Chairman, MIT Media Lab Director and board member of Sony, the MacArthur Foundation, The New York Times, the Knight Foundation and Mozilla; Dr. Ben Shapiro, former EVP of Worldwide Basic and External Research at Merck; Dr. John LaMattina, former President of R&D at Pfizer Global Research and Development; Mr. Christopher Viehbacher, former CEO and member of the board of directors of Sanofi; Dr. H. Robert Horvitz, Nobel Laureate, David H. Koch Professor at MIT and Investigator, Howard Hughes Medical Institute; Dr. Raju Kucherlapati, Paul C. Cabot Professor in the Harvard Medical School Department of Genetics, co-founder of Millennium Pharmaceuticals and Abgenix, and Member of President Obama's Commission for the Study of Bioethical Issues; and Daphne Zohar, PureTech's Founder and CEO, recognized as a healthcare innovator and leader by The Boston Globe, MIT's Technology Review, Scientific American, BioWorld and others.

PureTech Announces Board Changes

PureTech announced that Dame Marjorie Scardino, chairman of the MacArthur Foundation and former CEO of Pearson, has been appointed to PureTech's board of directors in the role of senior independent director and that current board member Joi Ito, MIT Media Lab's director, has been appointed board chairman. Dr. Ben Shapiro, PureTech's outgoing chairman and co-founder, former executive vice president of Basic & External Research at Merck, will remain an active member of the Board. PureTech is also expanding its core team with the addition of Julie DiCarlo, former head of global communications at Cubist Pharmaceuticals, as SVP of communications and investor relations; and Spencer Ball, former director of executive search/talent acquisition at PAREXEL, as Vice president of talent acquisition. Dame Marjorie Scardino served as chief executive of the economist for 12 years and then from 1997 through 2012 was the chief executive of Pearson plc. and the owner of Penguin Books and The Financial Times Group. She is currently the chairman of the MacArthur Foundation and is also a member of the non-profit boards of Oxfam, The Royal College of Art, and The Carter Center, as well as the for-profit boards of Twitter, where she sits on the audit committee, and IAG (the holding company of British Airways, Iberia and other airlines).

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
PRTC:LN 148.00 GBp +5.00

PRTC Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for PRTC.
View Industry Companies
 

Industry Analysis

PRTC

Industry Average

Valuation PRTC Industry Range
Price/Earnings -- Not Meaningful
Price/Sales -- Not Meaningful
Price/Book -- Not Meaningful
Price/Cash Flow -- Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact PURETECH HEALTH PLC, please visit www.puretechhealth.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.